AstraZeneca PLC

Oncology is AstraZeneca's largest business. It sells drugs that treat lung, breast, ovarian, and blood cancers. Two of its best-selling drugs, Tagrisso and Imfinzi, target specific gene changes found in cancer cells. Sales in this area grew faster than any other part of the company in 2025.肿瘤业务是阿斯利康最大的业务板块。公司销售治疗肺癌、乳腺癌、卵巢癌和血液癌的药物。其两款畅销药泰瑞沙（Tagrisso）和英飞凡（Imfinzi）针对癌细胞中特定的基因变化。2025年该板块的销售增速在公司各业务中居首。

• Tagrisso泰瑞沙 — A pill that treats a common type of lung cancer with a specific gene mutation.一种治疗特定基因突变型常见肺癌的口服药。
• Imfinzi英飞凡 — An injected drug that helps the immune system attack cancer cells, used for lung, bladder, and liver cancers.一种注射药物，可帮助免疫系统攻击癌细胞，用于治疗肺癌、膀胱癌和肝癌。
• Enhertu优赫得 — A targeted drug for breast, lung, and stomach cancers, made with a partner company.与合作公司共同开发的靶向药物，用于治疗乳腺癌、肺癌和胃癌。

This business sells medicine that protects the heart and kidneys and controls blood sugar. Its top drug, Farxiga, treats type 2 diabetes, heart failure, and chronic kidney disease. This makes it one of AstraZeneca's most widely used medicines, covering three different diseases with one pill.该业务销售保护心脏和肾脏、控制血糖的药物。其主打药物安达唐（Farxiga）可治疗2型糖尿病、心力衰竭和慢性肾病，是阿斯利康应用最广泛的药物之一，一种药可覆盖三种不同疾病。

• Farxiga安达唐 — A pill first made for diabetes, now also used to treat heart failure and kidney disease.最初用于治疗糖尿病的口服药，现在也用于治疗心力衰竭和肾病。

This business came mostly from AstraZeneca's purchase of Alexion in 2021. It sells high-price medicine for rare blood and nerve diseases, where few other treatments exist. Because these diseases are rare, prices per patient are high, but the total number of patients is small.该业务主要来自阿斯利康2021年收购的安莱昂（Alexion）。公司销售治疗罕见血液病和神经病的高价药物，而其他治疗方案很少。由于患病人数稀少，每位患者的药价很高，但患者总数不多。

• Ultomiris优立妥 — A long-acting drug for a rare blood disease that destroys red blood cells.一种长效药物，用于治疗一种破坏红细胞的罕见血液病。

This business treats lung diseases like asthma and chronic obstructive pulmonary disease (COPD), as well as some autoimmune conditions, where the body's immune system attacks itself. Its key drugs include inhalers and injectable biologic drugs that reduce inflammation.该业务治疗哮喘和慢性阻塞性肺病（COPD）等肺部疾病，以及一些自身免疫性疾病（即人体免疫系统攻击自身的疾病）。其主要药物包括吸入剂和可减轻炎症的生物注射药。

• Fasenra法赛那 — An injected biologic drug that treats severe asthma by reducing a type of white blood cell.一种注射生物药，通过减少一类白细胞来治疗重度哮喘。

This is AstraZeneca's smallest therapy area. It includes a preventive drug that protects newborn babies from a common respiratory virus. Sales fell in 2025 as demand for COVID-19-related products continued to decline.这是阿斯利康最小的治疗领域。其中包括一种可保护新生儿免受常见呼吸道病毒感染的预防性药物。由于新冠相关产品需求持续下降，2025年该板块销售额有所下降。

• Beyfortus倍福妥 — A preventive shot, made with a partner company, that protects babies from RSV, a common respiratory virus.与合作公司共同开发的预防性注射剂，可保护婴儿免受常见呼吸道病毒RSV感染。